Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dexcom (DXCM) Research & Development (2016 - 2026)

Dexcom has reported Research & Development over the past 17 years, most recently at $145.3 million for Q1 2026.

  • Quarterly Research & Development changed 0.07% to $145.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $599.2 million through Mar 2026, up 7.75% year-over-year, with the annual reading at $599.1 million for FY2025, 8.45% up from the prior year.
  • Research & Development was $145.3 million for Q1 2026 at Dexcom, down from $148.2 million in the prior quarter.
  • Over five years, Research & Development peaked at $157.5 million in Q3 2025 and troughed at $110.3 million in Q3 2022.
  • The 5-year median for Research & Development is $136.0 million (2024), against an average of $134.5 million.
  • The largest YoY upside for Research & Development was 24.22% in 2022 against a maximum downside of 22.36% in 2022.
  • A 5-year view of Research & Development shows it stood at $116.3 million in 2022, then rose by 17.02% to $136.1 million in 2023, then increased by 2.5% to $139.5 million in 2024, then increased by 6.24% to $148.2 million in 2025, then dropped by 1.96% to $145.3 million in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Research & Development are $145.3 million (Q1 2026), $148.2 million (Q4 2025), and $157.5 million (Q3 2025).